ANTONIOTTI, CARLOTTA Statistiche
ANTONIOTTI, CARLOTTA
DIPARTIMENTO DI RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer
2025-01-01 Acha-Sagredo, Amelia; Andrei, Pietro; Clayton, Kalum; Taggart, Emma; Antoniotti, Carlotta; Woodman, Chloé A; Afrache, Hassnae; Fourny, Constance; Armero, Maria; Moinudeen, Hafsa Kaja; Green, Mary; Bhardwaj, Nisha; Mikolajczak, Anna; Rodriguez-Lopez, Maria; Crawford, Marg; Connick, Emma; Lim, Steven; Hobson, Philip; Linares, Josep; Ignatova, Ekaterina; Pelka, Diana; Smyth, Elizabeth C; Diamantis, Nikolaos; Sosnowska, Dominika; Carullo, Martina; Ciraci, Paolo; Bergamo, Francesca; Intini, Rossana; Nye, Emma; Barral, Patricia; Mishto, Michele; Arnold, James N; Lonardi, Sara; Cremolini, Chiara; Fontana, Elisa; Rodriguez-Justo, Manuel; Ciccarelli, Francesca D
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer
2025-01-01 Moretto, Roberto; Germani, Marco Maria; Carullo, Martina; Conca, Veronica; Minelli, Alessandro; Giordano, Mirella; Bruno, Rossella; Rossini, Daniele; Gusmaroli, Eleonora; De Grandis, Maria Caterina; Antoniotti, Carlotta; Salvatore, Lisa; Passardi, Alessandro; Tamberi, Stefano; Scartozzi, Mario; Pietrantonio, Filippo; Lonardi, Sara; Ugolini, Clara; Masi, Gianluca; Cremolini, Chiara
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials
2025-01-01 Antoniotti, Carlotta; Marmorino, Federica; Rossini, Daniele; Schmoll, Hans Joachim; Lonardi, Sara; Tonini, Giuseppe; Borelli, Beatrice; Cupini, Samanta; Stein, Alexander; Moretto, Roberto; Bergamo, Francesca; Ronzoni, Monica; Germani, Marco Maria; Zaniboni, Alberto; Fazio, Roberta; De Grandis, Maria Caterina; Ongaro, Elena; Masi, Gianluca; Cremolini, Chiara
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
2025-01-01 Germani, Marco Maria; Borelli, Beatrice; Hashimoto, Tadayoshi; Nakamura, Yoshiaki; Oldani, Simone; Battaglin, Francesca; Bergamo, Francesca; Salvatore, Lisa; Stahler, Arndt; Antoniotti, Carlotta; Shitara, Kohei; Venook, Alan; Oki, Eiji; Muro, Kei; Ugolini, Clara; Soeda, Junpei; Lonardi, Sara; Pietrantonio, Filippo; Lenz, Heinz-Josef; Modest, Dominik Paul; Yoshino, Takayuki; Cremolini, Chiara
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
2025-01-01 Antoniotti, C; Carullo, M; Rossini, D; Pietrantonio, F; Salvatore, L; Lonardi, S; Tamberi, S; Sciortino, C; Conca, V; Calegari, M A; Ciracì, P; Tamburini, E; Bergamo, F; Boccaccio, C; Passardi, A; Ritorto, G; Ugolini, C; Aprile, G; Galon, J; Cremolini, C
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy
2025-01-01 Vetere, Guglielmo; Germani, Marco Maria; Antoniotti, Carlotta; Salvatore, Lisa; Pietrantonio, Filippo; Lonardi, Sara; Bensi, Maria; Ghelardi, Filippo; Calegari, Maria Alessandra; Intini, Rossana; Minelli, Alessandro; Sullo, Francesco Giulio; Boccaccio, Chiara; Taravella, Ada; Puccini, Alberto; Lavacchi, Daniele; Noto, Laura; Salati, Massimiliano; Scartozzi, Mario; Cremolini, Chiara
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
2025-01-01 Ciracì, P; Germani, M M; Pietrantonio, F; Manca, P; Lonardi, S; Busico, A; Bergamo, F; Burgio, V; Mannavola, F; Di Donato, S; Fenocchio, E; Palermo, F; Capone, I; De Grandis, M C; Pella, N; Scartozzi, M; Antonuzzo, L; Passardi, A; Claravezza, M; Salvatore, L; Tamberi, S; Randon, G; Conca, E; Conca, V; Antoniotti, C; Moretto, R; Masi, G; Boni, L; Rossini, D; Cremolini, C
Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO
2025-01-01 Germani, M. M.; Heinemann, V.; Rossini, D.; Fischer Von Weikersthal, L.; Pietrantonio, F.; Heinrich, K.; Stahler, A.; Lonardi, S.; Kaiser, F.; Decker, T.; Salvatore, L.; Weiss, L.; Morano, F.; Fuchs, M.; Bergamo, F.; Antoniotti, C.; Masi, G.; Stintzing, S.; Frumento, P.; Cremolini, C.; Modest, D. P.
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies
2025-01-01 Moretto, R; Rossini, D; Polito, Mariam Grazia; Antoniotti, Carlotta; Intini, Rossana; Conca, Veronica; Andena, Paola; Carullo, Martina; Salvatore, Lisa; Germani, Marco Maria; Bergamo, Francesca; Passardi, Alessandro; Ciracì, Paolo; Tamburini, Emiliano; Boccaccio, Chiara; Zaniboni, Alberto; Masi, Gianluca; Pietrantonio, Filippo; Lonardi, Sara; Cremolini, C
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
2024-01-01 Ciracì, Paolo; Studiale, Vittorio; Taravella, Ada; Antoniotti, Carlotta; Cremolini, Chiara
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
2024-01-01 Bond, Marinde J G; van Smeden, Maarten; Degeling, Koen; Cremolini, Chiara; Schmoll, Hans-Joachim; Antoniotti, Carlotta; Lonardi, Sara; Murgioni, Sabina; Rossini, Daniele; Ibach, Stefan; Koopman, Miriam; Swijnenburg, Rutger-Jan; Punt, Cornelis J A; May, Anne M; Kwakman, Johannes J M
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study
2024-01-01 Antoniotti, Carlotta; Rossini, Daniele; Pietrantonio, Filippo; Salvatore, Lisa; Lonardi, Sara; Tamberi, Stefano; Marmorino, Federica; Moretto, Roberto; Prisciandaro, Michele; Tamburini, Emiliano; Tortora, Giampaolo; Passardi, Alessandro; Bergamo, Francesca; Raimondi, Alessandra; Ritorto, Giuliana; Borelli, Beatrice; Conca, Veronica; Ugolini, Clara; Aprile, Giuseppe; Antonuzzo, Lorenzo; Gelsomino, Fabio; Martinelli, Erika; Pella, Nicoletta; Masi, Gianluca; Boni, Luca; Galon, Jerome; Cremolini, Chiara
Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials
2024-01-01 Conca, V; Ciracì, P; Boccaccio, C; Minelli, A; Antoniotti, C; Cremolini, C
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
2023-01-01 Antoniotti, Carlotta; Boccaccino, Alessandra; Seitz, Robert; Giordano, Mirella; Catteau, Aurélie; Rossini, Daniele; Pietrantonio, Filippo; Salvatore, Lisa; Mcgregor, Kimberly; Bergamo, Francesca; Conca, Veronica; Leonetti, Simone; Morano, Federica; Papiani, Giorgio; Tamburini, Emiliano; Bensi, Maria; Murgioni, Sabina; Ross, Douglas Teller; Passardi, Alessandro; Boquet, Isabelle; Nielsen, Tyler J; Galon, Jérôme; Varga, Matthew Gordon; Schweitzer, Brock L; Cremolini, Chiara
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
2023-01-01 Martini, G; Ciardiello, D; Famiglietti, V; Rossini, D; Antoniotti, C; Troiani, T; Napolitano, S; Esposito, L; Latiano, T P; Maiello, E; Del Re, M; Lonardi, S; Aprile, G; Santini, D; Masi, G; Avallone, A; Normanno, N; Pietrantonio, F; Pinto, C; Ciardiello, F; Cremolini, C; Martinelli, E
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study
2023-01-01 Moretto, Roberto; Rossini, Daniele; Catteau, Aurélie; Antoniotti, Carlotta; Giordano, Mirella; Boccaccino, Alessandra; Ugolini, Clara; Proietti, Agnese; Conca, Veronica; Kassambara, Alboukadel; Pietrantonio, Filippo; Salvatore, Lisa; Lonardi, Sara; Tamberi, Stefano; Tamburini, Emiliano; Poma, Anello Marcello; Fieschi, Jacques; Fontanini, Gabriella; Masi, Gianluca; Galon, Jérôme; Cremolini, Chiara
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response
2023-01-01 Hijazi, Assia; Antoniotti, Carlotta; Cremolini, Chiara; Galon, Jérôme
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
2023-01-01 Pietrantonio, Filippo; Bergamo, Francesca; Rossini, Daniele; Ghelardi, Filippo; De Grandis, Maria Caterina; Germani, Marco Maria; Barsotti, Giulia; Formica, Vincenzo; Frassineti, Giovanni Luca; Boscolo, Giorgia; Cinieri, Saverio; Di Donato, Samantha; Antonuzzo, Lorenzo; Antoniotti, Carlotta; Ambrosini, Margherita; Piva, Vittoria Matilde; Nichetti, Federico; Fassan, Matteo; Cremolini, Chiara; Lonardi, Sara
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies
2023-01-01 Fanotto, Valentina; Rossini, Daniele; Casagrande, Mariaelena; Bergamo, Francesca; Spagnoletti, Andrea; Santini, Daniele; Antoniotti, Carlotta; Cupini, Samanta; Daniel, Francesca; Nasca, Vincenzo; Vetere, Guglielmo; Zaniboni, Alberto; Borelli, Beatrice; Carullo, Martina; Conca, Veronica; Passardi, Alessandro; Tamburini, Emiliano; Masi, Gianluca; Pella, Nicoletta; Cremolini, Chiara
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials
2023-01-01 Rossini, Daniele; Boccaccino, Alessandra; Carullo, Martina; Antoniotti, Carlotta; Dima, Giovanni; Ciracì, Paolo; Marmorino, Federica; Moretto, Roberto; Masi, Gianluca; Cremolini, Chiara
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer | 1-gen-2025 | Acha-Sagredo, Amelia; Andrei, Pietro; Clayton, Kalum; Taggart, Emma; Antoniotti, Carlotta; Woodman, Chloé A; Afrache, Hassnae; Fourny, Constance; Armero, Maria; Moinudeen, Hafsa Kaja; Green, Mary; Bhardwaj, Nisha; Mikolajczak, Anna; Rodriguez-Lopez, Maria; Crawford, Marg; Connick, Emma; Lim, Steven; Hobson, Philip; Linares, Josep; Ignatova, Ekaterina; Pelka, Diana; Smyth, Elizabeth C; Diamantis, Nikolaos; Sosnowska, Dominika; Carullo, Martina; Ciraci, Paolo; Bergamo, Francesca; Intini, Rossana; Nye, Emma; Barral, Patricia; Mishto, Michele; Arnold, James N; Lonardi, Sara; Cremolini, Chiara; Fontana, Elisa; Rodriguez-Justo, Manuel; Ciccarelli, Francesca D | |
| Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer | 1-gen-2025 | Moretto, Roberto; Germani, Marco Maria; Carullo, Martina; Conca, Veronica; Minelli, Alessandro; Giordano, Mirella; Bruno, Rossella; Rossini, Daniele; Gusmaroli, Eleonora; De Grandis, Maria Caterina; Antoniotti, Carlotta; Salvatore, Lisa; Passardi, Alessandro; Tamberi, Stefano; Scartozzi, Mario; Pietrantonio, Filippo; Lonardi, Sara; Ugolini, Clara; Masi, Gianluca; Cremolini, Chiara | |
| FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials | 1-gen-2025 | Antoniotti, Carlotta; Marmorino, Federica; Rossini, Daniele; Schmoll, Hans Joachim; Lonardi, Sara; Tonini, Giuseppe; Borelli, Beatrice; Cupini, Samanta; Stein, Alexander; Moretto, Roberto; Bergamo, Francesca; Ronzoni, Monica; Germani, Marco Maria; Zaniboni, Alberto; Fazio, Roberta; De Grandis, Maria Caterina; Ongaro, Elena; Masi, Gianluca; Cremolini, Chiara | |
| Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials | 1-gen-2025 | Germani, Marco Maria; Borelli, Beatrice; Hashimoto, Tadayoshi; Nakamura, Yoshiaki; Oldani, Simone; Battaglin, Francesca; Bergamo, Francesca; Salvatore, Lisa; Stahler, Arndt; Antoniotti, Carlotta; Shitara, Kohei; Venook, Alan; Oki, Eiji; Muro, Kei; Ugolini, Clara; Soeda, Junpei; Lonardi, Sara; Pietrantonio, Filippo; Lenz, Heinz-Josef; Modest, Dominik Paul; Yoshino, Takayuki; Cremolini, Chiara | |
| Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study | 1-gen-2025 | Antoniotti, C; Carullo, M; Rossini, D; Pietrantonio, F; Salvatore, L; Lonardi, S; Tamberi, S; Sciortino, C; Conca, V; Calegari, M A; Ciracì, P; Tamburini, E; Bergamo, F; Boccaccio, C; Passardi, A; Ritorto, G; Ugolini, C; Aprile, G; Galon, J; Cremolini, C | |
| Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy | 1-gen-2025 | Vetere, Guglielmo; Germani, Marco Maria; Antoniotti, Carlotta; Salvatore, Lisa; Pietrantonio, Filippo; Lonardi, Sara; Bensi, Maria; Ghelardi, Filippo; Calegari, Maria Alessandra; Intini, Rossana; Minelli, Alessandro; Sullo, Francesco Giulio; Boccaccio, Chiara; Taravella, Ada; Puccini, Alberto; Lavacchi, Daniele; Noto, Laura; Salati, Massimiliano; Scartozzi, Mario; Cremolini, Chiara | |
| Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO | 1-gen-2025 | Ciracì, P; Germani, M M; Pietrantonio, F; Manca, P; Lonardi, S; Busico, A; Bergamo, F; Burgio, V; Mannavola, F; Di Donato, S; Fenocchio, E; Palermo, F; Capone, I; De Grandis, M C; Pella, N; Scartozzi, M; Antonuzzo, L; Passardi, A; Claravezza, M; Salvatore, L; Tamberi, S; Randon, G; Conca, E; Conca, V; Antoniotti, C; Moretto, R; Masi, G; Boni, L; Rossini, D; Cremolini, C | |
| Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO | 1-gen-2025 | Germani, M. M.; Heinemann, V.; Rossini, D.; Fischer Von Weikersthal, L.; Pietrantonio, F.; Heinrich, K.; Stahler, A.; Lonardi, S.; Kaiser, F.; Decker, T.; Salvatore, L.; Weiss, L.; Morano, F.; Fuchs, M.; Bergamo, F.; Antoniotti, C.; Masi, G.; Stintzing, S.; Frumento, P.; Cremolini, C.; Modest, D. P. | |
| The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies | 1-gen-2025 | Moretto, R; Rossini, D; Polito, Mariam Grazia; Antoniotti, Carlotta; Intini, Rossana; Conca, Veronica; Andena, Paola; Carullo, Martina; Salvatore, Lisa; Germani, Marco Maria; Bergamo, Francesca; Passardi, Alessandro; Ciracì, Paolo; Tamburini, Emiliano; Boccaccio, Chiara; Zaniboni, Alberto; Masi, Gianluca; Pietrantonio, Filippo; Lonardi, Sara; Cremolini, C | |
| Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm | 1-gen-2024 | Ciracì, Paolo; Studiale, Vittorio; Taravella, Ada; Antoniotti, Carlotta; Cremolini, Chiara | |
| Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer | 1-gen-2024 | Bond, Marinde J G; van Smeden, Maarten; Degeling, Koen; Cremolini, Chiara; Schmoll, Hans-Joachim; Antoniotti, Carlotta; Lonardi, Sara; Murgioni, Sabina; Rossini, Daniele; Ibach, Stefan; Koopman, Miriam; Swijnenburg, Rutger-Jan; Punt, Cornelis J A; May, Anne M; Kwakman, Johannes J M | |
| Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study | 1-gen-2024 | Antoniotti, Carlotta; Rossini, Daniele; Pietrantonio, Filippo; Salvatore, Lisa; Lonardi, Sara; Tamberi, Stefano; Marmorino, Federica; Moretto, Roberto; Prisciandaro, Michele; Tamburini, Emiliano; Tortora, Giampaolo; Passardi, Alessandro; Bergamo, Francesca; Raimondi, Alessandra; Ritorto, Giuliana; Borelli, Beatrice; Conca, Veronica; Ugolini, Clara; Aprile, Giuseppe; Antonuzzo, Lorenzo; Gelsomino, Fabio; Martinelli, Erika; Pella, Nicoletta; Masi, Gianluca; Boni, Luca; Galon, Jerome; Cremolini, Chiara | |
| Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials | 1-gen-2024 | Conca, V; Ciracì, P; Boccaccio, C; Minelli, A; Antoniotti, C; Cremolini, C | |
| An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer | 1-gen-2023 | Antoniotti, Carlotta; Boccaccino, Alessandra; Seitz, Robert; Giordano, Mirella; Catteau, Aurélie; Rossini, Daniele; Pietrantonio, Filippo; Salvatore, Lisa; Mcgregor, Kimberly; Bergamo, Francesca; Conca, Veronica; Leonetti, Simone; Morano, Federica; Papiani, Giorgio; Tamburini, Emiliano; Bensi, Maria; Murgioni, Sabina; Ross, Douglas Teller; Passardi, Alessandro; Boquet, Isabelle; Nielsen, Tyler J; Galon, Jérôme; Varga, Matthew Gordon; Schweitzer, Brock L; Cremolini, Chiara | |
| Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials | 1-gen-2023 | Martini, G; Ciardiello, D; Famiglietti, V; Rossini, D; Antoniotti, C; Troiani, T; Napolitano, S; Esposito, L; Latiano, T P; Maiello, E; Del Re, M; Lonardi, S; Aprile, G; Santini, D; Masi, G; Avallone, A; Normanno, N; Pietrantonio, F; Pinto, C; Ciardiello, F; Cremolini, C; Martinelli, E | |
| Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study | 1-gen-2023 | Moretto, Roberto; Rossini, Daniele; Catteau, Aurélie; Antoniotti, Carlotta; Giordano, Mirella; Boccaccino, Alessandra; Ugolini, Clara; Proietti, Agnese; Conca, Veronica; Kassambara, Alboukadel; Pietrantonio, Filippo; Salvatore, Lisa; Lonardi, Sara; Tamberi, Stefano; Tamburini, Emiliano; Poma, Anello Marcello; Fieschi, Jacques; Fontanini, Gabriella; Masi, Gianluca; Galon, Jérôme; Cremolini, Chiara | |
| Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response | 1-gen-2023 | Hijazi, Assia; Antoniotti, Carlotta; Cremolini, Chiara; Galon, Jérôme | |
| Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV | 1-gen-2023 | Pietrantonio, Filippo; Bergamo, Francesca; Rossini, Daniele; Ghelardi, Filippo; De Grandis, Maria Caterina; Germani, Marco Maria; Barsotti, Giulia; Formica, Vincenzo; Frassineti, Giovanni Luca; Boscolo, Giorgia; Cinieri, Saverio; Di Donato, Samantha; Antonuzzo, Lorenzo; Antoniotti, Carlotta; Ambrosini, Margherita; Piva, Vittoria Matilde; Nichetti, Federico; Fassan, Matteo; Cremolini, Chiara; Lonardi, Sara | |
| Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies | 1-gen-2023 | Fanotto, Valentina; Rossini, Daniele; Casagrande, Mariaelena; Bergamo, Francesca; Spagnoletti, Andrea; Santini, Daniele; Antoniotti, Carlotta; Cupini, Samanta; Daniel, Francesca; Nasca, Vincenzo; Vetere, Guglielmo; Zaniboni, Alberto; Borelli, Beatrice; Carullo, Martina; Conca, Veronica; Passardi, Alessandro; Tamburini, Emiliano; Masi, Gianluca; Pella, Nicoletta; Cremolini, Chiara | |
| Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials | 1-gen-2023 | Rossini, Daniele; Boccaccino, Alessandra; Carullo, Martina; Antoniotti, Carlotta; Dima, Giovanni; Ciracì, Paolo; Marmorino, Federica; Moretto, Roberto; Masi, Gianluca; Cremolini, Chiara |